Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Clinical trial NCT06092086 · RECRUITING
Trial details
- NCT number
- NCT06092086
- Sponsor
- Guangdong Association of Clinical Trials
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-18
- Primary completion
- 2025-08-01
- Enrollment
- 126
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.